Current Report Filing (8-k)
March 04 2019 - 5:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported)
March 4, 2019
INTEC PHARMA LTD.
(Exact name of registrant as specified in
its charter)
|
Israel
|
001-37521
|
N/A
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
12 Hartom St.
Har Hotzvim
|
|
|
|
|
Jerusalem, Israel
|
9777512
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
|
+ 972-2-586-4657
|
|
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report)
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 7.01. Regulation FD Disclosure.
Intec Pharma Ltd. (the
“Company”) is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a slide presentation with respect to the
Company’s recently completed Accordion Pill Carbidopa/Levodopa three times daily PK study which the Company intends to
use at key opinion leader events and at meetings with the investor community.
The furnishing of the slide
presentation is not an admission as to the materiality of any information therein. The information contained in the presentation
materials is summary information that is intended to be considered in the context of more complete information included in the
Company’s filings with the SEC and other public announcements that the Company has made and may make from time to time by
press release or otherwise. All information contained in the presentation materials is subject to the disclaimer regarding forward-looking
statements at the beginning of the presentation.
The information furnished
pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and
shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such
filing, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: March 4, 2019
|
|
INTEC PHARMA LTD.
|
|
|
|
|
|
By:
|
/s/ Nir Sassi
|
|
|
|
Nir Sassi
|
|
|
|
Chief Financial Officer
|
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2023 to Apr 2024
